Key Takeaways:
AbbVie Inc. (NYSE: ABBV) announced a $1.4 billion investment to build a new pharmaceutical manufacturing campus in Durham, North Carolina, marking its largest single-campus capital project to date.
"Our investment in North Carolina represents a significant milestone for AbbVie as our largest capital investment to date and an important expansion of our manufacturing footprint into a new region of the United States," said Robert A. Michael, chairman and chief executive officer at AbbVie.
The 185-acre campus is expected to create 734 jobs over the next four years, including roles for engineers, scientists, and manufacturing technicians. Construction is slated to begin in 2026 and finish by the end of 2028. The facility will serve as the company's U.S. center of excellence for small volume parenteral (SVP) drug product manufacturing, supporting its immunology, neuroscience, and oncology pipeline.
This project is part of AbbVie's broader $100 billion commitment to U.S. research and development and capital investments over the next decade. The expansion into North Carolina's Research Triangle Park area strengthens AbbVie's domestic supply chain and production capacity for next-generation medicines for patients in the U.S. and worldwide.
The new Durham campus represents AbbVie's first major investment in North Carolina. The state's governor lauded the move.
"When you combine our world-renowned research and innovation with a strong, thriving life sciences hub, North Carolina quickly becomes the premier location for biopharmaceutical companies to do business," said Governor Josh Stein.
The first phase of construction will include advanced manufacturing facilities, next-generation laboratories, a warehouse, and administrative offices. The project is also expected to generate over 2,000 construction jobs during its development.
This announcement follows over $2.2 billion in U.S. manufacturing investment commitments from AbbVie in the last 12 months, creating more than 1,300 jobs across North Carolina, Illinois, Arizona, and Massachusetts.
The new campus will focus on small volume parenterals, which are sterile injectable products typically under 100 mL, such as vials and prefilled syringes. This capability is critical for delivering many of AbbVie's complex biologic and targeted therapies.
The investment signals confidence in AbbVie's long-term pipeline and its strategy to enhance its manufacturing infrastructure with advanced technologies, including artificial intelligence. For investors, the significant capital outlay underscores a commitment to scaling production to meet future demand for its key growth products. The next major milestone will be the commencement of construction later this year.
This article is for informational purposes only and does not constitute investment advice.
